Conquering Knowledge Gaps Concerning Therapeutic Advances in T-Cell Lymphoma

A learning opportunity provided by i3 Health has demonstrated significant knowledge gains regarding therapeutic advances in T-cell lymphoma (TCL). T-cell lymphoma is a rare type of non-Hodgkin lymphoma with many different subtypes, including peripheral TCL, anaplastic large cell lymphoma, adult T-cell leukemia/lymphoma, angioimmunoblastic TCL, and cutaneous TCL. TCL makes up less than 15% of total non-Hodgkin lymphomas. Mycosis fungoides (MF), the most common form of cutaneous TCL, frequently mi...

Continue reading

Diagnosis and Evidence-Based Management of T-Cell Lymphoma With Aaron Goodman, MD

Oncology Data Advisor™ · Diagnosis and Evidence-Based Management of T-Cell Lymphoma T-cell lymphoma (TCL) is an uncommon subtype accounting for approximately 15% of all cases of non-Hodgkin lymphoma in the United States (LRF, 2022). Compared with its B-cell counterpart, TCL has a poor prognosis and is associated with a 5-year survival rate of less than 20%. The clinical and pathologic presentations of TCL are varied and often nonspecific, making diagnosis and treatment challenging (...

Continue reading

Duvelisib/Romidepsin for Patients With Relapsed/Refractory Peripheral T-Cell Lymphoma: Steven M. Horwitz, MD

For patients with relapsed/refractory T-cell lymphoma (TCL), standard therapies provide an overall response rate of only 25% to 35%, and novel therapeutic options are greatly needed. In a study recently presented at the American Society of Hematology (ASH) 63rd Annual Meeting & Exposition in Atlanta, Georgia, a team of researchers led by Dr. Steven M. Horwitz, medical oncologist at Memorial Sloan Kettering Cancer Center, investigated the efficacy of the phosphoinositide-3-kinase inhibitor du...

Continue reading

Recent Advances in T-Cell Lymphoma: A Conversation with Dr. Steven Horwitz

·

In this podcast, Dr. Steven Horwitz of  Memorial Sloan Kettering Cancer Center discusses recent progress in the treatment and management of T-cell lymphoma. Listen now to hear more!

Continue reading

Copyright © Oncology Data Advisor. All rights reserved.